Patents by Inventor Natalie Wayne Pursell

Natalie Wayne Pursell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR INHIBITING MITOCHONDRIA AMIDOXIME REDUCING COMPONENT 1 (MARC1) EXPRESSION
    Publication number: 20230340490
    Abstract: Oligonucleotides are provided herein that inhibit MARC1 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with MARC1 expression.
    Type: Application
    Filed: April 14, 2023
    Publication date: October 26, 2023
    Inventors: Henryk Dudek, Wen Han, Natalie Wayne Pursell, Chengjung Lai, William Geoffrey Haynes, Zhihao Ding
  • COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSION
    Publication number: 20230220398
    Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
    Type: Application
    Filed: January 6, 2023
    Publication date: July 13, 2023
    Inventors: Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen
  • Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression
    Patent number: 11655473
    Abstract: Oligonucleotides are provided herein that inhibit MARC1 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with MARC1 expression.
    Type: Grant
    Filed: May 27, 2022
    Date of Patent: May 23, 2023
    Assignees: Novo Nordisk A/S, Dicerna Pharmaceuticals, Inc.
    Inventors: Henryk Dudek, Wen Han, Natalie Wayne Pursell, Chengjung Lai, William Geoffrey Haynes, Zhihao Ding
  • COMPOSITIONS AND METHODS FOR INHIBITING ALPHA-1 ANTITRYPSIN EXPRESSION
    Publication number: 20230107967
    Abstract: This disclosure relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Application
    Filed: October 29, 2021
    Publication date: April 6, 2023
    Inventors: Bob Dale BROWN, Natalie Wayne PURSELL, Chengjung LAI
  • Compositions and methods for inhibiting nuclear receptor subfamily 1 group H member 3 (NR1H3) expression
    Patent number: 11578329
    Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: February 14, 2023
    Assignees: Novo Nordisk A/S, Dicerna Pharmaceuticals, Inc.
    Inventors: Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen
  • COMPOSITIONS AND METHODS FOR INHIBITING MITOCHONDRIA AMIDOXIME REDUCING COMPONENT 1 (MARC1) EXPRESSION
    Publication number: 20230042451
    Abstract: Oligonucleotides are provided herein that inhibit MARC1 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with MARC1 expression.
    Type: Application
    Filed: May 27, 2022
    Publication date: February 9, 2023
    Inventors: Henryk Dudek, Wen Han, Natalie Wayne Pursell, Chengjung Lai, William Geoffrey Haynes, Zhihao Ding
  • COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSION
    Publication number: 20220340912
    Abstract: Oligonucleotides are provided herein that inhibit NR1H3 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with NR1H3 expression.
    Type: Application
    Filed: April 19, 2022
    Publication date: October 27, 2022
    Inventors: Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen